Our clinical trial provides substantial evidence for an anti-tumour activity of celecoxib based on global transcriptional changes and suppression of Ki-67 protein in primary breast cancer tissues, encouraging further clinical trials of celecoxib or its derivative molecules in breast cancer. The gene discussed is MKI67; the disease is breast cancer.